Champions Oncology, Inc. · NASDAQ:CSBR
Champions Oncology — Investor Presentation (June 2016)
21 slides from Champions Oncology's investor presentation, June 2016
Slide 1: Investor Presentation
Investor Presentation June 2016 1
Slide 2: Notice of Forward Looking Statements
Notice of Forward Looking Statements This presentation contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking
Slide 3: Why Invest in Champions Oncology?
Why Invest in Champions Oncology? Experience Innovation Customer Base Progress Experienced management Innovative technology Large and growing 5 years of revenue growth and team platform customer base of scientific progress pharmaceutical and biotech companies 3
Slide 4: Our Senior Management Team
Our Senior Management Team Chairman of the Board CEO President David Sidransky, MD Joel Ackerman Ronnie Morris, MD 15 years at Warburg Pincus Founder and CMO of MDVIP – Johns Hopkins University, Professor investing in healthcare leading provider of personalized and Director Head and Neck Cancer Boar
Slide 5: The Problem with Oncology Drugs
The Problem with Oncology Drugs Failure Rates Remain High Skyrocketing R&D Costs $1.2 billion average capital outlay 93% failure rate in per approved biopharmaceutical clinical trials Despite Advances, Unsustainable Increases in Response Rates Remain Low 60% Oncology Drug Costs Response Rates 40% Av
Slide 6: Champions' Platform Addresses the Challenges
Champions’ Platform Addresses the Challenges Created by Oncology Clinical Trials CHALLENGE OF ONCOLOCY CHAMPIONS SOLUTION CLINICAL TRIALS Cost per patient: > $100,000 Time to Complete: Clinical Trial 8 years Simulation Platform Chance of Success: 7% 6
Slide 7: Simulating Patient Response to Oncology Drugs with Patient Derived Xenografts (PDX)
Simulating Patient Response to Oncology Drugs with Patient Derived XenoGrafts (PDX) Patient Implant Treatment Measurement χ χ ✔ χ Patient tumor is implanted Mice are dosed The effect of each in immune-compromised with different anti-tumor therapy on tumor mice therapies growth is measured 7
Slide 8: The Predictive Power of PDX
The Predictive Power of PDX A growing body of evidence demonstrates positive predictive value for Champions TumorGraft® PDX models. Clinical Accuracy Measures Result 95% Cl Positive Predictive Value (PPV) 87% (80/92) 77% - 93% Negative Predictive Value (NPV) 94% (32/34) 79% - 99% Source: 126 TumorGr
Slide 9: Champions TumorGraft is an Immortalized Model of an Individual Patient
Champions TumorGraft is an Immortalized Model of an Individual Patient for Predicting Response Patient Data Perpetual Tissue Stock Genomic Data 9
Slide 10: The Champions TumorGraft Platform Today
The Champions TumorGraft® Platform Today 700 PDX models in our tumor bank that reflect characteristics of patients who enroll in clinical trials (late stage, pretreated and metastic) 10
Slide 11: The Value of Patient Derived Xenografts
The Value of Patient Derived Xenografts Economics Speed 90%+ lower costs than a 6 months to study completion human clinical trial versus 2-3 years for human trial PDX Repeatability Predictability Same patient can be run 90%+ accuracy in predicting with multiple drugs for human response head-to-head
Slide 12: Champions Has Built a Successful Core Business
Champions Has Built a Successful Core Business 450 Studies Completed 100 Customers Served 34% Revenue Growth Ranging in size from $25,000 Including 16 of the top 20 5 year cumulative annual to more than $1 million pharma companies and 84 growth rate in core business other pharma and biotech serving
Slide 13: Three Strategies for Accelerating Revenue Growth
Three Strategies for Accelerating Revenue Growth Grow the Platform Immune Oncology Innovative Study Designs 13
Slide 14: Growing the Breadth and Depth of the TumorBank
Champions is Employing Novel Approaches to Grow the Breadth and Depth of the TumorBank Deepening the Bank Broadening the Bank Patients Research Custom Model Development 14
Slide 15: Champions ImmunoGraft Development
Champions ImmunoGraft™ Development A novel platform using Champions TumorGraft platform in humanized mice Proliferating Screening against human immune immuno-oncology cells measured agents Murine immune system Tumors from patients or eradicated and human banked tumors implanted and immune system Imp
Slide 16: Innovative Study Designs Enable Larger Studies
Innovative Study Designs Enable Larger Studies Recent bookings will drive accelerated revenue growth in our upcoming fiscal year. Cost Per Drug by Phase Total Available ($ millions) Market Size1 ($ millions) $150 $1,500 $120 $90 $1,000 $690 $60 $30 $500 $0 $488 Pre-clinical Phase 1 Phase 2 Phase 3 $
Slide 17: Champions Operational Capabilities
Champions Operational Capabilities Corporate Headquarters Primary Lab & Vivarium Hackensack, NJ Baltimore, MD Approximately 70 FTEs Johns Hopkins Science + Technology Center 20MDs or PhDs AAALAC accredited ISO 9001:2008 certified CLIA certified Facility Breakdown Implantation Centers 8,000 square fe
Slide 18: Historical and Future Financial Results
Historical and Future Financial Results Current Financial Results LTM Revenue: $11.6 mm 5 year core revenue growth(1): 34% Cash flow positive before R&D expenditure(2) Quarterly cash burn(2): $800,000 Fiscal Year 2017 Financial Projections Accelerating revenue growth(3) Cash flow positiv
Slide 19: Upcoming Milestones
Upcoming Milestones Strategic Sponsored New Product Commercial R&D Introductions Partnerships Collaborations 19
Slide 20: Recent Financing Priced on June 9, 2016
Recent Financing Priced on June 9, 2016 Offering Details Gross Proceeds: $5 million(1) Price per share: $2.25(1) Capital Runway: Current cash expected to get company to cash flow positive Trading Details More than doubled public float Bid/ask spread improved to ~$0.04 since offering(2) A
Slide 21: Champions Oncology
CHAMPIONS ONCOLOGY One University Plaza | Suite 307 Hackensack, NJ OUR EMAIL OUR PHONE OUR WEBSITE sforeman@championsoncology.com 201.808.8400 www.championsoncology.com 21
Champions Oncology — Investor Presentation (June 2016) on 6ix